CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report

Manmeet Ahluwalia; Ahmad Ozair; Atulya Khosla

CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report

Manmeet Ahluwalia
, Ahmad Ozair
, Atulya Khosla

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 15 2023
Event	Neuro-Oncology - Duration: Nov 15 2023 → …

Conference

Conference	Neuro-Oncology
Period	11/15/23 → …

Cite this

@conference{0fb9ae0d0c2b460bad1e38f9c15062a9,

title = "CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report",

author = "Manmeet Ahluwalia and Ahmad Ozair and Atulya Khosla",

note = "Ahluwalia, M., Ozair, A., Khosla, A., Patel, N., Elson, P., Murphy, E., Chao, S., Suh, J., Stevens, G., \& Peereboom, D. (2023). CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report. Neuro-Oncology, 25(Supplement\_5), v78-v78. https://doi.org/10.1093/neuonc/noad179.0303; Neuro-Oncology ; Conference date: 15-11-2023",

year = "2023",

month = nov,

day = "15",

language = "American English",

}

TY - CONF

T1 - CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report

AU - Ahluwalia, Manmeet

AU - Ozair, Ahmad

AU - Khosla, Atulya

N1 - Ahluwalia, M., Ozair, A., Khosla, A., Patel, N., Elson, P., Murphy, E., Chao, S., Suh, J., Stevens, G., & Peereboom, D. (2023). CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report. Neuro-Oncology, 25(Supplement_5), v78-v78. https://doi.org/10.1093/neuonc/noad179.0303

PY - 2023/11/15

Y1 - 2023/11/15

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/5070

M3 - Presentation

T2 - Neuro-Oncology

Y2 - 15 November 2023

ER -

CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report

Conference

Other files and links

Cite this